본문 바로가기

Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans

문서 유형
연구출판물 · 학술지 논문
등재
Nature IndexSCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
CANCER RESEARCH74(4) · pp.1265 · 2013
피인용
Web of Science 219
JCR IF
JCR 2012 8.65
ISSN
0008-5472

저자

  1. Breitbach, Caroline J.제1저자Jennerex Inc, United States
  2. Arulanandam, RozanneCentre for Innovative Cancer Therapeutics, Ottawa Hospital, Research Institute, Canada
  3. De Silva, NaomiCentre for Innovative Cancer Therapeutics, Ottawa Hospital, Research Institute, Canada
  4. Thorne, Steve H.Departments of Surgery and Immunology, University of Pittsburgh, United States
  5. Patt, RichardRadMD, United States
  6. Daneshmand, ManijehJennerex Inc, United States
  7. Moon, AnneCentre for Innovative Cancer Therapeutics, Ottawa Hospital, Research Institute, Canada
  8. Ilkow, CarolinaCentre for Innovative Cancer Therapeutics, Ottawa Hospital, Research Institute, Canada
  9. Burke, JamesJennerex Inc, United States
  10. 황태호Pusan National University, South Korea
  11. 허정RadMD, United States
  12. 조몽Jennerex Inc, United States
  13. Chen, HannahExperimental Therapeutics, Toronto General Research Institute, University Health Network, Canada
  14. Angarita, Fernando A.Jennerex Inc, United States
  15. Addison, ChristinaCentre for Innovative Cancer Therapeutics, Ottawa Hospital, Research Institute, Canada
  16. McCart, J. AndreaDepartment of Surgery, University of Toronto, Canada
  17. Bell, John C.Jennerex Inc, United States
  18. Kirn, David H.교신저자Jennerex Inc, United States

초록

Efforts to selectively target and disrupt established tumor vasculature have largely failed to date. We hypothesized that a vaccinia virus engineered to target cells with activation of the ras/MAPK signaling pathway (JX-594) could specifically infect and express transgenes (hGM-CSF, beta-galactosidase) in tumor-associated vascular endothelial cells in humans. Efficient replication and transgene expression in normal human endothelial cells in vitro required either VEGF or FGF-2 stimulation. Intravenous infusion in mice resulted in virus replication in tumor-associated endothelial cells, disruption of tumor blood flow, and hypoxia within 48 hours; massive tumor necrosis ensued within 5 days. Normal vessels were not affected. In patients treated with intravenous JX-594 in a phase I clinical trial, we showed dose-dependent endothelial cell infection and transgene expression in tumor biopsies of diverse histologies. Finally, patients with advanced hepatocellular carcinoma, a hypervascular and VEGF-rich tumor type, were treated with JX-594 on phase II clinical trials. JX-594 treatment caused disruption of tumor perfusion as early as 5 days in both VEGF receptor inhibitor-naive and -refractory patients. Toxicities to normal blood vessels or to wound healing were not evident clinically or on MRI scans. This platform technology opens up the possibility of multifunctional engineered vaccinia products that selectively target and infect tumor-associated endothelial cells, as well as cancer cells, resulting in transgene expression, vasculature disruption, and tumor destruction in humans systemically. Cancer Res; 73(4); 1265-75. (C) 2012 AACR.

키워드

ENDOTHELIAL GROWTH-FACTORBREAST-CARCINOMA CELLSHEPATOCELLULAR-CARCINOMATHYMIDINE KINASEIN-VIVOGM-CSFPOXVIRUSTHERAPYCANCERJX-594

식별자

WoS UID
000315029800002